Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QuANTUM-Wild: Quizartinib with induction/consolidation chemotherapy and as maintenance in newly diagnosed FLT3-ITD-negative AML
CTR20244780Phase 3Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Quizartinib arm with Placebo arm (2 arms). Primary endpoint: Overall survival (OS). Started Apr 2025; status: active.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20244780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244780.